• Home >
  • Publications >
  • CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

1 Mar 2017Oncogene

DOI : 10.1038/onc.2016.284

Authors

S Lefort, A Thuleau, Y Kieffer, P Sirven, I Bieche, E Marangoni, A Vincent-Salomon, F Mechta-Grigoriou